Animal well being firm Zenex Animal Well being India has acquired a majority stake in Netherlands-based VievePharm, a specialist in pure animal vitaminfor an undisclosed sum, the corporate stated on Friday.
The deal provides Zenex a producing and gross sales base in Western Europe and expands its portfolio of pure and natural animal well being merchandise, as regulatory stress mounts on veterinary antibiotic use throughout the European Union.
Headquartered in Enter, Netherlands, VievePharm specialises in phytogenic formulations for the livestockequine and pet care markets.
The acquisition builds on Zenex’s 2023 buy of Ayurvet, which established its Ayurvedic animal well being portfolio.
VievePharm’s experience in bolus know-how used to ship minerals, nutritional vitamins and udder well being help will likely be built-in into Zenex’s broader product providing globally.
The deal comes because the EU’s Farm to Fork Technique targets a 50 per cent discount in veterinary antibiotic gross sales by 2030 in comparison with 2018 ranges, a pattern Zenex stated would profit its mixed naturals portfolio.
“By combining VievePharm’s superior bolus know-how and European market entry with our R&D depth and world distribution, we’re positioned to supply holistic, science-backed options,” Zenex Managing Director and CEO Arun Atrey stated in a press release.
Zenex presently has operations throughout Asia, Africa and elements of the CIS area. The acquisition is meant to speed up its entry into Western European markets utilizing VievePharm’s established distribution community.